Chronic kidney disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• AKT 0
• mTOR 1
• STAT3 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• STING 0
• MAPK 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• IL-1 1
• JAK 0
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CommunityRx-Kidney Health

  NCT07237295· University of North Carolina, Chapel Hill· Updated 5 Nov 2026

  “Unanticipated operational challenges. No safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Novo Nordisk A/S· Updated 4 Nov 2026

  “Interim futility analysis showed primary endpoint not achieved”Registry text, quoted unchanged. Source

• Terminated

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· Alexion Pharmaceuticals, Inc.· Updated 29 Oct 2026

  “The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.”Registry text, quoted unchanged. Source

• Suspended

  Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Updated 29 Oct 2026

  “Recruitment temporarily paused.”Registry text, quoted unchanged. Source

• Terminated

  Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CKD

  NCT05018845· The Foundation for Orthopaedics and Regenerative Medicine· Updated 20 Oct 2026

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source

• Withdrawn

  Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

  NCT07786571· Sun Yat-sen University· Updated 16 Oct 2026

  “The study was withdrawn because the protocol was revised and would be replaced by an updated study design, prior to participant enrollment.”Registry text, quoted unchanged. Source

• Terminated

  Solv Multi-Pass Hemodialysis System In-Center Clinical Study

  NCT07216885· Mozarc Medical US LLC· Updated 1 Oct 2026

  “Due to funding the study has been stopped. All subjects enrolled have completed the follow-up and have exited the study.”Registry text, quoted unchanged. Source

• Withdrawn

  Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

  NCT06995144· Sarfez Pharmaceuticals, Inc.· Updated 28 Sept 2026

  “No participants enrolled”Registry text, quoted unchanged. Source

• Withdrawn

  A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

  NCT07223502· Sarfez Pharmaceuticals, Inc.· Updated 22 Sept 2026

  “No recruitment”Registry text, quoted unchanged. Source

• Terminated

  Impact of the Characteristics of Acute Renal Failure in Intensive Care on the Long-term Renal Prognosis: Prospective Multicenter Cohort Study

  NCT05247502· University Hospital, Clermont-Ferrand· Updated 17 Sept 2026

  “due to a lack of funding and human resources to carry out data collection”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety and Efficacy of Empagliflozin in Hemodialysis

  NCT05786443· NYU Langone Health· Source

• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· AstraZeneca· Source

• Dine and DASH Into Wellness Pilot Study

  NCT07175896· Duke University· Source

• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Boehringer Ingelheim· Source

• Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

  NCT07348484· Instituto de Investigación Biomédica de Salamanca· Source

• Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation

  NCT06234410· University of Edinburgh· Source

• Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health

  NCT07918508· Florida International University· Source

• Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population

  NCT05981183· NYU Langone Health· Source

• CommunityRx-Kidney Health

  NCT07237295· University of North Carolina, Chapel Hill· Source

• REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial

  NCT07654231· University of Texas Southwestern Medical Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 87
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 90
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 69
• Machine Learning 174
• Deep Learning 22
• Cohort Studies 548
• Genome-Wide Association Study 78

See which targets of this disease your abstract mentions, and go to the people working on them.